
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Interim data from three studies released at the 62nd annual conferenceof the American Academy of Dermatology support preliminary data presentedlast month demonstrating that tacrolimus ointment (Protopic, Fujisawa) ismore effective than pimecrolimus cream (Elidel, Novartis) in the treatmentof adult and pediatric patients with atopic dermatitis.